RAS mutant colorectal cancer
Conditions
Interventions
Experimental group:fluzoparib combined with bevacizumab
Sponsors
Shanghai Dongfang Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Aged over 18 years; 2. ECOG score 0-1 points; 3. Metastatic or unresectable advanced colorectal cancer with RAS gene mutation; 4. Received bevacizumab combined with standard first-line chemotherapy and the efficacy evaluation was CR/PR at the time of enrollment; 5. The main organ function and bone marrow function are normal; 6. Patients voluntarily participate and sign the informed consent form, and can cooperate with the study according to the requirements of the program.
Exclusion criteria
Exclusion criteria: 1. Participate in another interventional clinical trial within 4 weeks before enrollment; 2. Received PARP inhibitor therapy before enrollment; 3. Suffered from or still accompanied by other systemic malignant tumors in the past 5 years; 4. Severe infections requiring antibiotics, antivirals or antifungal control; 5. Other situations deemed inappropriate by the investigator for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Safety; | — |
Countries
China
Contacts
Public ContactGao Yong
Shanghai Dongfang Hospital
Outcome results
None listed